KYMR Kymera Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026
$107.39
· of 52w range
· above low
· to high
$55.2652w low
$130.0552w high
Market Cap (MRQ)
$8.89B
P/E (TTM)
-33.0
EPS (TTM)
$-3.25
Revenue (TTM)
$105M
your badges
52W Range
$55–$130
Analyst Rating
BUY
Price Target
$139
P/E
-33.0
ROE
-24.2%
Net Profit Margin
-285.3%
Your badge strip is empty — pin a metric anywhere on this page.
KYMR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$107.39
Market Cap (MRQ)
$8.89B
P/E (TTM)
-33.0
EPS (TTM)
$-3.25
Revenue (TTM)
$105M
ROE (TTM)
-24.2%
52W Range
$55–$130
KYMR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Kymera Therapeutics, Inc. - Common Stock Company overview from Wikipedia
sectorHealthcare
industryBiotechnology
employees273
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$39M2019-12-31 → 2025-12-31
EPS$-3.692020-12-31 → 2025-12-31
Free Cash Flow$-234M2020-12-31 → 2025-12-31
Net margin-285.3%2020-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | KYMR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -33.05Y avg ≈-16.8 | ≈-16.8 | · | · | |
| P/S (TTM) | 84.75Y avg ≈72.8 | ≈72.8 | 28.1 | Overvalued | |
| P/B (MRQ) | 5.95Y avg ≈4.3 | ≈4.3 | 8.1 | Undervalued | |
| Price / FCF (TTM) | -37.45Y avg ≈-18.4 | ≈-18.4 | · | · | |
| Price / Cash Flow (TTM) | -37.65Y avg ≈-18.7 | ≈-18.7 | · | · | |
| Price / Tangible Book | 5.55Y avg ≈4.3 | ≈4.3 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | KYMR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -333.5%5Y avg ≈-428.0% | ≈-428.0% | -38.2% | Weak | |
| EBITDA Margin (TTM) | -325.7%5Y avg ≈-417.8% | ≈-417.8% | -38.2% | Weak | |
| Pretax Margin | -794.0% | · | 4.3% | Weak | |
| Net Profit Margin (TTM) | -285.3%5Y avg ≈-385.0% | ≈-385.0% | -42.8% | Weak | |
| ROA (TTM) | -21.6%5Y avg ≈-24.1% | ≈-24.1% | -20.7% | In line | |
| ROE (TTM) | -24.2%5Y avg ≈-27.9% | ≈-27.9% | -22.4% | In line | |
| ROIC | -22.1% | · | -19.6% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | KYMR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 10.35Y avg ≈6.7 | ≈6.7 | 8.1 | Strong liquidity | |
| Quick Ratio | 4.35Y avg ≈1.8 | ≈1.8 | 5.0 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | KYMR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -16.7%5Y avg ≈17.9% | ≈17.9% | · | · | |
| Revenue CAGR 3Y | -5.7%5Y avg ≈4.3% | ≈4.3% | · | · | |
| Revenue CAGR 5Y | 2.9% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | KYMR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.1 | ≈0.1 | 0.1 | Weak | |
| Revenue / Employee | ≈$143.6K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.16%
Next Report
Nov 02, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.62 | $-0.73 | 14.8% |
| March 31, 2026 | $-0.71 | $-0.90 | 21.0% | |
| Dec. 31, 2025 | $-0.97 | $-0.81 | -19.4% | |
| Sept. 30, 2025 | $-0.94 | $-0.82 | -14.6% | |
| June 30, 2025 | $-0.95 | $-0.83 | -15.0% | |
| March 31, 2025 | $-0.82 | $-0.93 | 12.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $47M | $79M | $47M | $73M | $34M | $3M | |
| Cost of Revenue | $39M | $47M | $79M | $47M | · | · | · | |
| R&D Expense | $317M | $240M | $189M | $164M | $137M | $62M | $37M | |
| SG&A Expense | $68M | $64M | $55M | $44M | $36M | $18M | $8M | |
| Operating Expenses | $389M | $309M | $244M | $208M | $173M | $80M | $45M | |
| Operating Income | $-349M | $-262M | $-166M | $-161M | $-101M | $-46M | $-42M | |
| Other Non-op | $38M | $38M | $19M | $6M | $313.0K | $711.0K | $959.0K | |
| Pretax Income | $-311M | · | · | · | · | · | · | |
| Income Tax | $0 | · | · | $0 | $0 | $0 | $0 | |
| Net Income | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | $-41M | |
| EPS (Basic) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| EPS (Diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| Shares (Basic) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| Shares (Diluted) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| EBITDA | $-341M | $-254M | $-162M | $-158M | $-98M | $-45M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $357M | $120M | $110M | $68M | $48M | $31M | $76M | |
| Receivables | $0 | $0 | $15M | $0 | · | · | · | |
| Prepaid Expense | $23M | $22M | $12M | $10M | $9M | $5M | $888.0K | |
| Current Assets | $871M | $510M | $405M | $419M | $451M | $302M | $93M | |
| PP&E (Net) | $43M | $50M | $48M | $13M | $12M | $11M | $4M | |
| PP&E (Gross) | $65M | $67M | $59M | $20M | $16M | $13M | $5M | |
| Accum. Depreciation | $22M | $16M | $10M | $7M | $4M | $2M | $1M | |
| Other Non-current Assets | $9M | $2M | $2M | $3M | $2M | $30.0K | $2M | |
| Total Assets | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Accounts Payable | $4M | $6M | $7M | $4M | $4M | $4M | $3M | |
| Accrued Liabilities | $42M | $35M | $34M | $28M | $23M | $10M | $5M | |
| Current Liabilities | $83M | $68M | $86M | $71M | $93M | $111M | $35M | |
| Capital Leases | $67M | $72M | $77M | $12M | $13M | $14M | $17M | |
| Other Non-current Liabilities | · | $0 | $0 | $248.0K | $66.0K | $100.0K | · | |
| Total Liabilities | $163M | $142M | $181M | $113M | $146M | $203M | $82M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $5.0K | $4.0K | · | |
| Retained Earnings | $-1.07B | $-755M | $-531M | $-384M | $-229M | $-129M | $-76M | |
| AOCI | $2M | $-1M | $-552.0K | $-5M | $-660.0K | $-128.0K | $6.0K | |
| Stockholders' Equity | $1.58B | $836M | $395M | $490M | $460M | $284M | $-74M | |
| Liabilities + Equity | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Shares Outstanding | 81,323,532 | 64,890,193 | 55,585,305 | 55,039,380 | 51,536,181 | 44,482,186 | 1,929,516 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $8M | $7M | $4M | $3M | $2M | $2M | $825.0K | |
| Stock-based Comp | $60M | $55M | $43M | $35M | $25M | $5M | $1M | |
| Other Non-cash | $10M | $-33M | $-3M | $-37M | $-56M | $127M | · | |
| Operating Cash Flow | $-233M | $-195M | $-103M | $-153M | $-129M | $88M | $18M | |
| CapEx | $1M | $13M | $34M | $3M | $2M | $9M | $532.0K | |
| Investing Cash Flow | $-521M | $-404M | $140M | $21M | $-100M | $-423M | $-16M | |
| Financing Cash Flow | $991M | $609M | $4M | $153M | $250M | $289M | $35M | |
| Net Change in Cash | $237M | $10M | $41M | $20M | $21M | $-45M | $36M | |
| Free Cash Flow | $-234M | $-207M | $-137M | $-156M | $-131M | $79M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | · | |
| Net Margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | · | |
| Pretax Margin | -794.0% | · | · | · | · | · | · | |
| EBITDA Margin | -869.9% | -540.2% | -206.1% | -338.0% | -134.7% | -130.9% | · | |
| ROA | -22.9% | -28.8% | -24.9% | -25.6% | -18.3% | -15.1% | · | |
| ROE | -24.4% | -25.9% | -37.2% | -30.9% | -21.3% | -15.8% | · | |
| ROIC | -22.1% | · | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 | 2.7 | · | |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 | 0.3 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | · | |
| Receivables Turnover | · | 6.3 | 10.5 | · | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $19.42 | $12.88 | · | $8.91 | $8.92 | $6.38 | · | |
| Revenue / Share | $0.46 | $0.63 | $1.35 | $0.87 | · | · | · | |
| Cash Flow / Share | $-2.76 | $-2.59 | $-1.76 | $-2.84 | · | · | · | |
| Cash / Share | $4.39 | $1.85 | · | $1.24 | $0.93 | $0.70 | · | |
| EPS (TTM) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% | · | · | |
| Revenue CAGR 3Y | -5.7% | -13.5% | 32.2% | · | · | · | · | |
| Revenue CAGR 5Y | 2.9% | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $39M | $47M | $79M | $47M | $73M | $34M | · | |
| Net Income TTM | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | · | |
| Market Cap | $6.33B | $2.61B | · | $1.37B | $3.27B | $2.76B | · | |
| P/E | -21.1 | -13.5 | -10.1 | -8.7 | -30.4 | -19.7 | · | |
| P/S | 161.4 | 55.5 | · | 29.3 | 44.9 | 81.0 | · | |
| P/B | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Tangible Book | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Cash Flow | -27.2 | -13.4 | · | -9.0 | -25.4 | 31.3 | · | |
| P / FCF | -27.0 | -12.6 | · | -8.8 | -25.1 | 34.9 | · | |
| Earnings Yield | -4.7% | -7.4% | -9.9% | -11.5% | -3.3% | -5.1% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | $48M | $5M | $17M | $9M | $16M | $10M | |
| Cost of Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | · | · | · | · | · | · | |
| R&D Expense | $119M | $98M | $84M | $74M | $78M | $80M | $72M | $60M | $59M | $49M | $53M | $48M | $46M | $42M | $43M | $44M | |
| SG&A Expense | $21M | $20M | $17M | $17M | $18M | $16M | $16M | $15M | $17M | $14M | $14M | $14M | $14M | $13M | $12M | $11M | |
| Operating Expenses | $141M | $119M | $101M | $95M | $96M | $97M | $88M | $76M | $77M | $68M | $67M | $62M | $60M | $55M | $55M | $54M | |
| Operating Income | $-76M | $-84M | $-98M | $-93M | $-85M | $-74M | $-81M | $-72M | $-51M | $-58M | $-19M | $-58M | $-43M | $-45M | $-39M | $-45M | |
| Other Non-op | $14M | $15M | $11M | $10M | $8M | $9M | $10M | $10M | $9M | $9M | $5M | $5M | $5M | $4M | $4M | $2M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $100.0K | $0 | · | $0 | |
| Net Income | $-61M | $-69M | $-87M | $-82M | $-77M | $-66M | $-71M | $-62M | $-42M | $-49M | $-14M | $-53M | $-39M | $-41M | $-35M | $-43M | |
| EPS (Basic) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| EPS (Diluted) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| Shares (Basic) | 98,177,158 | 97,534,269 | · | 87,300,286 | 80,449,405 | 80,146,531 | · | 76,125,975 | 73,059,398 | 70,770,320 | · | 58,421,859 | 58,326,963 | 58,187,038 | · | 54,535,514 | |
| Shares (Diluted) | 98,177,158 | 97,534,269 | · | 87,300,286 | 80,449,405 | 80,146,531 | · | 76,125,975 | 73,059,398 | 70,770,320 | · | 58,421,859 | 58,326,963 | 58,187,038 | · | 54,535,514 | |
| EBITDA | $-76M | $-82M | · | $-93M | $-85M | $-72M | · | $-72M | $-51M | $-56M | · | $-58M | $-43M | $-44M | · | $-45M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124M | $144M | $357M | $113M | $336M | $90M | $120M | $111M | $68M | $94M | $110M | $81M | $52M | $50M | $68M | $156M | |
| Receivables | $20M | · | · | · | $40M | · | · | $0 | $0 | $0 | · | · | · | · | · | · | |
| Prepaid Expense | $26M | $27M | $23M | $23M | $23M | $18M | $22M | $17M | $14M | $15M | · | $14M | $14M | $11M | · | $9M | |
| Current Assets | $737M | $677M | $871M | $528M | $728M | $501M | $510M | $569M | $525M | $537M | · | $376M | $385M | $412M | · | $494M | |
| PP&E (Net) | $40M | $42M | $43M | $45M | $49M | $49M | $50M | $51M | $52M | $49M | · | $36M | $27M | $17M | · | $13M | |
| PP&E (Gross) | $66M | $66M | $65M | $67M | $69M | $67M | $67M | $65M | $64M | $60M | · | $46M | $36M | $25M | · | $19M | |
| Accum. Depreciation | $26M | $24M | $22M | $22M | $20M | $18M | $16M | $14M | $12M | $11M | · | $10M | $9M | $8M | · | $6M | |
| Other Non-current Assets | $7M | $8M | $9M | $7M | $5M | $3M | $2M | $0 | $2M | $2M | · | $3M | $3M | $3M | · | $3M | |
| Total Assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Accounts Payable | $9M | $13M | $4M | $6M | $6M | $10M | $6M | $6M | $7M | $7M | · | $5M | $4M | $6M | · | $6M | |
| Accrued Liabilities | $48M | $35M | $42M | $29M | $28M | $23M | $35M | $27M | $24M | $16M | · | $26M | $22M | $19M | · | $25M | |
| Current Liabilities | $71M | $63M | $83M | $72M | $88M | $59M | $68M | $67M | $62M | $56M | · | $63M | $55M | $62M | · | $91M | |
| Capital Leases | $64M | $66M | $67M | $68M | $70M | $71M | $72M | $74M | $75M | $76M | · | $77M | $71M | $64M | · | $12M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | $8.0K | $230.0K | $237.0K | · | $256.0K | |
| Total Liabilities | $136M | $129M | $163M | $156M | $160M | $132M | $142M | $142M | $141M | $157M | · | $157M | $147M | $152M | · | $126M | |
| Common Stock | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $-1.20B | $-1.14B | $-1.07B | $-979M | $-897M | $-820M | $-755M | $-684M | $-621M | $-579M | · | $-516M | $-464M | $-425M | · | $-349M | |
| AOCI | $-7M | $-4M | $2M | $2M | $279.0K | $-58.0K | $-1M | $2M | $-2M | $-2M | · | $-2M | $-4M | $-3M | · | $-6M | |
| Stockholders' Equity | $1.51B | $1.54B | $1.58B | $946M | $971M | $786M | $836M | $893M | $685M | $711M | $395M | $396M | $435M | $462M | $490M | $513M | |
| Liabilities + Equity | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Shares Outstanding | 82,788,253 | 82,182,101 | 81,323,532 | 71,741,174 | 70,557,442 | 65,112,714 | 64,890,193 | 64,748,226 | 61,572,383 | 61,353,146 | · | 55,450,239 | 55,390,259 | 55,276,226 | · | 54,751,429 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $891.0K | $895.0K | $900.0K | $879.0K | $818.0K | $767.0K | |
| Stock-based Comp | $19M | $16M | $14M | $16M | $15M | $14M | $14M | $15M | $14M | $12M | $11M | $12M | $11M | $9M | $9M | $9M | |
| Other Non-cash | · | $-38M | · | · | · | $-30M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-54M | $-89M | $-67M | $-27M | $-60M | $-79M | $-62M | $-50M | $-43M | $-40M | $8M | $-32M | $-35M | $-44M | $-40M | $-34M | |
| CapEx | $473.0K | $434.0K | $106.0K | $181.0K | $695.0K | $467.0K | $936.0K | $-189.0K | $5M | $7M | $12M | $8M | $11M | $4M | $373.0K | $1M | |
| Investing Cash Flow | $20M | $-143M | $-394M | $-235M | $60M | $49M | $69M | $-158M | $16M | $-331M | $19M | $61M | $36M | $25M | $-50M | $-37M | |
| Financing Cash Flow | $14M | $19M | $705M | $40M | $246M | $258.0K | $3M | $251M | $1M | $354M | $2M | $-206.0K | $1M | $1M | $2M | $150M | |
| Net Change in Cash | $-20M | $-213M | $244M | $-223M | $246M | $-30M | $10M | $43M | $-26M | $-16M | $29M | $29M | $2M | $-18M | $-87M | $79M | |
| Free Cash Flow | · | $-89M | · | · | · | $-80M | · | · | · | $-47M | · | · | · | $-48M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -116.3% | -244.9% | · | -3347.4% | -736.8% | -336.8% | · | -1927.9% | -198.5% | -562.2% | · | -1216.4% | -262.7% | -478.8% | · | -469.9% | |
| Net Margin | -94.2% | -201.5% | · | -2973.0% | -667.6% | -296.8% | · | -1670.3% | -164.0% | -472.0% | · | -1118.2% | -235.0% | -432.4% | · | -450.2% | |
| EBITDA Margin | -116.3% | -239.0% | · | -3347.4% | -736.8% | -327.5% | · | -1927.9% | -198.5% | -548.0% | · | -1216.4% | -262.7% | -469.5% | · | -469.9% | |
| ROA | -4.4% | -5.3% | · | -7.7% | -7.8% | -7.3% | · | -7.9% | -6.0% | -6.6% | · | -8.9% | -7.0% | -7.0% | · | -6.7% | |
| ROE | -4.9% | -5.9% | · | -8.9% | -9.2% | -8.8% | · | -9.7% | -7.5% | -8.3% | · | -11.6% | -9.3% | -9.2% | · | -8.6% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.3 | 10.8 | · | 7.4 | 8.3 | 8.5 | · | 8.5 | 8.5 | 9.6 | · | 5.9 | 7.1 | 6.6 | · | 5.4 | |
| Quick Ratio | 2.0 | 2.3 | · | 1.6 | 4.3 | 1.5 | · | 1.7 | 1.1 | 1.7 | · | 1.3 | 1.0 | 0.8 | · | 1.7 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 2.2 | · | · | · | 0.6 | · | · | · | · | · | · | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.23 | $18.73 | · | $13.19 | $13.77 | $12.07 | · | $13.79 | $11.12 | $11.59 | · | $7.13 | $7.86 | $8.36 | · | $9.37 | |
| Revenue / Share | $0.66 | $0.35 | · | $0.03 | $0.14 | $0.28 | · | $0.05 | $0.35 | $0.15 | · | $0.08 | $0.28 | $0.16 | · | $0.18 | |
| Cash Flow / Share | · | $-0.91 | · | · | · | $-0.99 | · | · | · | $-0.56 | · | · | · | $-0.76 | · | · | |
| Cash / Share | $1.50 | $1.75 | · | $1.57 | $4.76 | $1.38 | · | $1.71 | $1.10 | $1.52 | · | $1.46 | $0.95 | $0.91 | · | $2.84 | |
| EPS (TTM) | $-3.25 | $-3.58 | · | $-3.60 | $-3.48 | $-3.11 | · | $-2.34 | $-2.42 | $-2.51 | · | $-2.86 | $-2.75 | $-2.86 | · | $-2.95 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $105M | $51M | · | $44M | $45M | $59M | · | $88M | $89M | $79M | · | $47M | $52M | $47M | · | $46M | |
| Net Income TTM | $-300M | $-315M | · | $-295M | $-275M | $-241M | · | $-167M | $-158M | $-155M | · | $-167M | $-158M | $-159M | · | $-154M | |
| Market Cap | $9.49B | $6.84B | · | $4.06B | $3.08B | $1.78B | · | $3.06B | $1.84B | $2.47B | · | $771M | $1.27B | $1.64B | · | $1.19B | |
| P/E | -35.3 | -23.3 | · | -15.7 | -12.5 | -8.8 | · | -20.2 | -12.3 | -16.0 | · | -4.9 | -8.4 | -10.4 | · | -7.4 | |
| P/S | 90.4 | 133.0 | · | 92.8 | 68.9 | 30.3 | · | 35.0 | 20.8 | 31.1 | · | 16.5 | 24.6 | 35.1 | · | 25.9 | |
| P/B | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Tangible Book | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Cash Flow | · | -77.0 | · | · | · | -22.5 | · | · | · | -62.3 | · | · | · | -37.3 | · | · | |
| Earnings Yield | -2.8% | -4.3% | · | -6.4% | -8.0% | -11.4% | · | -4.9% | -8.1% | -6.2% | · | -20.6% | -12.0% | -9.7% | · | -13.6% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $39M | $47M | $79M | $47M | $73M |
| Operating Margin % | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% |
| Net Income | $-311M | $-224M | $-147M | $-155M | $-100M |
| Diluted EPS | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-234M | $-207M | $-137M | $-156M | $-131M |
Institutional owners (13F) 305 filers · $10.2B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
305
Value held
$10.2B
New positions
53
Exited positions
23
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 53 (+7 vs prior Q) | 23 (-13 vs prior Q) | 101 (+5 vs prior Q) | 80 (+8 vs prior Q) | +431K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $1,416,089,213 | 12,349,256 | 13.95% | Shares |
| BAKER BROS. ADVISORS LP | $992,725,940 | 8,657,242 | 9.78% | Shares |
| Avoro Capital Advisors LLC | $857,129,238 | 7,474,747 | 8.44% | Shares |
| BlackRock, Inc. | $635,066,535 | 5,538,210 | 6.25% | Shares |
| VANGUARD GROUP INC | $487,685,380 | 6,267,644 | 4.80% | Shares |
| BVF INC/IL | $444,008,203 | 3,872,052 | 4.37% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $421,415,461 | 3,675,028 | 4.15% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $343,114,771 | 2,992,193 | 3.38% | Shares |
| Siren, L.L.C. | $336,651,626 | 2,935,830 | 3.32% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $336,255,785 | 2,932,378 | 3.31% | Shares |
| Atlas Venture Life Science Advisors, LLC | $326,527,526 | 2,847,541 | 3.22% | Shares |
| STATE STREET CORP | $313,877,705 | 2,737,226 | 3.09% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $208,316,264 | 1,816,331 | 2.05% | Shares |
| Capital Research Global Investors | $159,262,984 | 1,388,881 | 1.57% | Shares |
| GOLDMAN SACHS GROUP INC | $136,151,475 | 1,187,333 | 1.34% | Shares |
| UBS Group AG | $115,561,789 | 1,007,777 | 1.14% | Shares |
| Driehaus Capital Management LLC | $105,408,448 | 919,233 | 1.04% | Shares |
| Merck & Co., Inc. | $88,544,161 | 772,165 | 0.87% | Shares |
| NORGES BANK | $86,833,399 | 757,246 | 0.86% | Shares |
| FEDERATED HERMES, INC. | $85,933,469 | 749,398 | 0.85% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $85,421,500 | 745,152 | 0.84% | Shares |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $84,955,104 | 740,866 | 0.84% | Shares |
| ALLIANCEBERNSTEIN L.P. | $81,750,884 | 981,521 | 0.81% | Shares |
| Holocene Advisors, LP | $72,996,514 | 636,579 | 0.72% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $72,951,379 | 875,872 | 0.72% | Shares |
| NORTHERN TRUST CORP | $66,727,276 | 581,907 | 0.66% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $60,744,024 | 529,729 | 0.60% | Shares |
| FRANKLIN RESOURCES INC | $59,060,783 | 515,050 | 0.58% | Shares |
| EVENTIDE ASSET MANAGEMENT, LLC | $57,811,287 | 504,210 | 0.57% | Shares |
| JENNISON ASSOCIATES LLC | $57,676,487 | 502,978 | 0.57% | Shares |
| Woodline Partners LP | $57,434,534 | 500,868 | 0.57% | Shares |
| Rock Springs Capital Management LP | $51,963,399 | 453,156 | 0.51% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $51,570,654 | 449,731 | 0.51% | Shares |
| Boxer Capital Management, LLC | $49,204,897 | 429,100 | 0.48% | Shares |
| Pictet Asset Management Holding SA | $44,984,008 | 395,540 | 0.44% | Shares |
| BANK OF AMERICA CORP /DE/ | $43,378,055 | 378,286 | 0.43% | Shares |
| BRAIDWELL LP | $43,363,951 | 378,163 | 0.43% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $43,100,784 | 375,868 | 0.42% | Shares |
| TWO SIGMA INVESTMENTS, LP | $42,585,457 | 371,374 | 0.42% | Shares |
| Clearbridge Investments, LLC | $39,815,871 | 347,221 | 0.39% | Shares |
| Octagon Capital Advisors LP | $35,547,700 | 310,000 | 0.35% | Shares |
| Nextech Invest Ltd. | $31,981,004 | 278,896 | 0.31% | Shares |
| Alyeska Investment Group, L.P. | $31,701,095 | 276,455 | 0.31% | Shares |
| TD Asset Management Inc | $31,293,443 | 272,900 | 0.31% | Shares |
| VOYA INVESTMENT MANAGEMENT LLC | $30,951,039 | 269,914 | 0.30% | Shares |
| TWO SIGMA ADVISERS, LP | $29,085,378 | 373,800 | 0.29% | Shares |
| Commodore Capital LP | $28,667,500 | 250,000 | 0.28% | Shares |
| RTW INVESTMENTS, LP | $27,520,800 | 240,000 | 0.27% | Shares |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $26,799,869 | 233,713 | 0.26% | Shares |
| GILDER GAGNON HOWE & CO LLC | $26,265,508 | 229,053 | 0.26% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, LAMPERT MARK N, Hrustanovic Gorjan ×2 filings | June 26, 2026 | 6.30% | Amendment | · | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×4 filings | Dec. 11, 2025 | 10.90% | Amendment | Capital structure | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II, L.P., BVF II GP LLC, BIOTECHNOLOGY VALUE TRADING FUND OS, L.P., BVF PARTNERS OS LTD., BVF GP HOLDINGS LLC, BVF PARTNERS L.P., BVF INC., MARK N. LAMPERT, GORJAN HRUSTANOVIC ×5 filings | Jan. 9, 2024 | · | Initial filing | · | SEC |
| Vertex Pharmaceuticals Incorporated ×2 filings | June 5, 2023 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 25 insiders · 10 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Nello Mainolfi | Chief Executive Officer | Oct. 1, 2026 M | 666,568 | 0 | 26 | $-36,819,541 |
| Bruce N. Jacobs | Chief Financial Officer | June 30, 2026 M | 244,883 | 0 | 15 | $-9,956,105 |
| Jeremy G Chadwick | Chief Operating Officer | May 27, 2026 S | 44,018 | 0 | 29 | $-15,599,618 |
| Brian Adams | Chief Legal Officer | Sept. 4, 2026 S | 50,254 | 0 | 3 | $-744,297 |
| Terence Rooney | Chief Medical Officer | July 27, 2026 A | 38,000 | 0 | 0 | $0 |
| Noah Goodman | Chief Business Officer | July 1, 2026 S | 47,179 | 0 | 9 | $-2,223,845 |
| Jared Gollob | Chief Medical Officer | March 2, 2026 A | 117,134 | 0 | 18 | $-9,134,491 |
| Ellen Chiniara | Chief Legal Officer | March 3, 2025 A | 80,085 | 0 | 0 | $0 |
| Elaine Caughey | Chief Business Officer | March 1, 2023 A | 18,986 | 0 | 0 | $0 |
| Richard Chesworth | Chief Scientific Officer | Aug. 27, 2021 M | 0 | 0 | 0 | $0 |
| Bruce Booth | Director | June 29, 2026 S | 462,856 | 0 | 160 | $-226,031,370 |
| Hrustanovic Gorjan | Director | June 24, 2026 A | · | 0 | 0 | $0 |
| Elena Ridloff | Director | June 24, 2026 A | 0 | 0 | 4 | $-1,285,644 |
| Pamela Esposito | Director | June 24, 2026 A | 1,000 | 0 | 12 | $-3,054,174 |
| Jeffrey W. Albers | Director | June 24, 2026 A | 0 | 0 | 3 | $-744,757 |
| Victor Sandor | Director | June 24, 2026 A | · | 0 | 0 | $0 |
| John Maraganore | Director | June 24, 2026 A | · | 0 | 0 | $0 |
| Leigh Morgan | Director | June 18, 2024 A | · | 0 | 0 | $0 |
| Joanna Horobin | Director | June 7, 2024 M | 0 | 0 | 0 | $0 |
| Donald William Nicholson | Director | June 15, 2022 A | · | 0 | 0 | $0 |
| Steven Edward Hall | Director | Aug. 25, 2020 C | 2,192,249 | 0 | 0 | $0 |
| Andrew Hedin | Director | Aug. 20, 2020 A | · | 0 | 0 | $0 |
| Atlas Venture Fund X, L.P. | 10% owner | May 18, 2021 J | 5,763,012 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% owner | Aug. 25, 2020 C | 959,211 | 0 | 0 | $0 |
| Alexandria Venture Investments, LLC | 10% owner | Aug. 25, 2020 C | 467,932 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 49 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| HAPS · Harbor ETF Trust | 2.21% | 36,388 NS | July 31, 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1.75% | 45,819 SH | Oct. 2, 2026 | Daily |
| GURU · Global X Funds | 1.41% | 8,375 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.90% | 43,133 NS | July 31, 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0.80% | 3,605 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.62% | 543,907 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.61% | 5,875 SH | Oct. 2, 2026 | Daily |
| ESSC · Strategy Shares | 0.44% | 1,522 NS | July 31, 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.43% | 24,014 NS | July 31, 2026 | N-PORT |
| IWO · iShares Trust | 0.40% | 487,324 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.35% | 55,351 SH | Aug. 19, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.25% | 589 NS | July 31, 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0.25% | 2,092 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.24% | 1,600,729 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.22% | 360,394 SH | Aug. 19, 2026 | Daily |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 14,574 NS | July 31, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.21% | 871,540 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.21% | 29,987 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.19% | 32,324 SH | Aug. 19, 2026 | Daily |
| FFSM · FIDELITY COVINGTON TRUST | 0.18% | 25,352 NS | July 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.14% | 17,965 NS | July 31, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.13% | 7,208 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.10% | 152,728 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.10% | 8,361 SH | Sept. 11, 2026 | Daily |
| ESML · iShares Trust | 0.09% | 22,280 SH | Sept. 11, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.09% | 1,509,269 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.08% | 19,721 SH | Oct. 2, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.08% | 726,357 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.08% | 9,461 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.08% | 134,854 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.07% | 21,341 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.06% | 3,284 SH | Sept. 11, 2026 | Daily |
| FBCG · FIDELITY COVINGTON TRUST | 0.05% | 31,560 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.02% | 113,415 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.02% | 5,280 NS | July 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 3,058 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.01% | 15,117 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.01% | 2,447 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.01% | 2,089,726 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 49,584 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 5,163 SH | Aug. 19, 2026 | Daily |
| ITOT · iShares Trust | 0.01% | 81,928 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.01% | 17,103 SH | Sept. 11, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.01% | 13,837 SH | Aug. 19, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 9,292 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 151 NS | July 31, 2026 | N-PORT |
| IWN · iShares Trust | · | 102,204 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 2,398 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 6,014 SH | Sept. 11, 2026 | Daily |
KYMR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 30 analysts
BUY
Median target
$135.50
+26.2%
10 33.3%
Strong Buy
16 53.3%
Buy
4 13.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
22 analysts · 2026-10-04Mean target $138.64 +29.1%
← Below all targets
Current price $107.39
Low$111.00
Mean$138.64
High$180.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 5, 2026